<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> are a group of bone marrow stem cell disorders which were considered refractory to chemotherapy until recently </plain></SENT>
<SENT sid="1" pm="."><plain>Low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> was given to 6 patients with symptomatic <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and 2 patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>5 patients responded to therapy, 3 of whom with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> achieved normalization of peripheral blood counts </plain></SENT>
<SENT sid="3" pm="."><plain>Therapy was well tolerated, <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> was the predominant side effect </plain></SENT>
<SENT sid="4" pm="."><plain>This preliminary trial demonstrates that patients with symptomatic <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, particularly patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> may be benefited by low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> therapy </plain></SENT>
</text></document>